Status:
COMPLETED
Gene Therapy for X-linked Chronic Granulomatous Disease (CGD) in Children
Lead Sponsor:
University of Zurich
Collaborating Sponsors:
Goethe University
Conditions:
Chronic Granulomatous Disease
Eligibility:
MALE
1-18 years
Phase:
PHASE1
PHASE2
Brief Summary
The aim of the study is to evaluate the side effects and risks after infusion of retroviral gene corrected autologous CD34+ cells of the peripheral blood of chemotherapy conditioned (busulphan) childr...
Eligibility Criteria
Inclusion
- x-linked Chronic Granulomatous Disease
- history of life-threatening severe infections
- no HLA-matched related or unrelated donor
- therapy resistent life threatening infections/organ dysfunction
- no other treatment options e.g. HSCT
Exclusion
- \> 18 years of age
- HIV infection
- life expectancy \> 2 years
- infections treatable by conventional therapy (antibiotics, antimycotics, allogeneic granulocytes)
Key Trial Info
Start Date :
June 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2011
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT00927134
Start Date
June 1 2004
End Date
September 1 2011
Last Update
September 27 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Children's Hospital
Zurich, Switzerland, CH-8032